18 citations
,
September 2022 in “Cold Spring Harbor Perspectives in Biology” Controlling immune responses with biomaterials can reduce scarring and improve skin regeneration.
June 2023 in “Research Square (Research Square)” Hair loss in male pattern baldness is linked to changes in immune cell behavior around hair follicles.
June 2023 in “Romanian Medical Journal” The case shows how hard it is to tell apart Multiple Autoimmune Syndrome from other similar autoimmune conditions, but correct diagnosis is key for treatment to work.
20 citations
,
September 2003 in “Journal of Investigative Dermatology” Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.
21 citations
,
May 2014 in “Toxicological Sciences” Toluene diisocyanate exposure can cause immune sensitization by interacting with proteins in hair follicles and sebaceous glands.
September 2025 in “Radboud University Press eBooks” AHR ligands could treat inflammatory skin diseases.
April 2019 in “Journal of Investigative Dermatology” Blocking LFA-1 prevents hair loss in mice.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
May 2025 in “Journal of the Egyptian Womenʼs Dermatologic Society” Hair follicles in nonsegmental vitiligo are better protected from immune attacks than in alopecia areata.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.
101 citations
,
July 1998 in “Journal of Investigative Dermatology” UVB exposure in human skin causes macrophages to produce more IL-10 and less IL-12, leading to immunosuppression.
24 citations
,
February 2011 in “The American journal of pathology” AIRE protein, defective in APECED patients, is found in skin and hair cells and interacts with cytokeratin 17.
July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
1 citations
,
April 2016 in “Journal of Investigative Dermatology” Targeting specific T cells may help treat alopecia areata.
110 citations
,
July 2017 in “Immunology” Skin's Regulatory T cells are crucial for maintaining skin health and could be targeted to treat immune-related skin diseases and cancer.
1 citations
,
May 2023 in “The Journal of Dermatology” Allergen-specific immunotherapy can significantly improve hair loss and dermatitis symptoms in severe cases.
39 citations
,
November 2015 in “Pediatric Nephrology” Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
January 2018 in “Indian Dermatology Online Journal” DM and AA may share a common cause.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
July 2022 in “British Journal of Dermatology”
24 citations
,
March 2018 in “Experimental Dermatology” Treg dysfunction is linked to various autoimmune skin diseases, and understanding Treg properties is key for new treatments.
September 2025 in “PeerJ” FCER1A and RGS1 may help diagnose and treat systemic lupus erythematosus.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
86 citations
,
June 2018 in “Cochrane library” Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
21 citations
,
January 2021 in “Journal of infection and chemotherapy” Men, diabetes, and high inflammation levels lead to higher COVID-19 antibodies.
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
1 citations
,
April 2017 in “Journal of Dermatology and Dermatologic Surgery” IVIG therapy was linked to hair regrowth in two patients with hair loss, but it's not recommended due to its risks and costs.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
248 citations
,
August 2015 in “Pharmacological Research” Vaccines are generally safe, but rare autoimmune reactions can occur, often influenced by genetics.